Has adequate hematological and physiological functions.
Patient with adequate organ functions
Adequate organ functions
Patient with adequate bone marrow reserve, hepatic and renal functions
INCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED BY WASH U GPS LABORATORY): The patient must have completed radiation therapy and be at least 1 week from the last systemic therapy administration, with adequate recovery of bone marrow and organ functions, before starting neratinib
INCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): The patient must have completed radiation therapy and be at least 1 week from the last systemic therapy administration, with adequate recovery of bone marrow and organ functions, before starting neratinib
Adequate organ and bone marrow functions evaluated during the 14 days prior to enrollment as follows:
Adequate bone marrow and renal functions
Patients need to have adequate kidney, bone marrow, and liver functions =< 14 days of registration as specified below:
Acceptable liver and renal functions defined as:
Adequate hepatic and renal functions as defined by:
Adequate hepatic and renal functions as defined by:
Adequate organ functions
Poor vital organ functions defined as:
Adequate bone marrow function, renal and liver functions
Adequate other organ functions
Have adequate values, bone marrow, renal and liver functions at screening as defined below:
Adequate bone marrow, liver and renal functions (tests must be performed within 14 days prior to enrollment).
Subjects who have adequate organ functions
Adequate organ system functions as defined by the laboratory assessments.
Adequate renal functions within 48 hours prior to induction chemotherapy
Adequate renal functions
Adequate hematopoietic, renal, and hepatic functions defined as:
Adequate performance status and hematological, liver and kidney functions
Adequate haematological, hepatic and renal functions defined by the protocol
Subjects who have adequate hematological, renal, hepatic and respiratory functions defined.
Adequate organ and bone marrow functions
Patients must have adequate bone marrow, renal, hepatic, and neurologic functions
Have adequate organ functions.
Adequate hematological, hepatic and renal functions.
Adequate hematologic, hepatic, renal, and coagulation functions
Patient must have completed radiation therapy with adequate recovery of bone marrow and organ functions, before starting neratinib
Subjects must have adequate bone marrow, liver, kidney, and coagulation functions.
Participant has adequate organ functions, evidenced by the following:
Adequate bone marrow function, renal and liver functions
Adequate bone marrow, liver, and renal functions.
Adequate organ functions
Have clinically adequate hepatic and renal functions as defined by:
Adequate haematological, renal (creatinine < 2xULN), cardiac and liver functions
Adequate Bone Marrow, Renal and liver Functions.
Eligible study subjects must exhibit acceptable liver, bone marrow, renal and cardiac functions as assessed by laboratory tests, ECG and ECHO or MUGA scan.
Adequate organ and bone marrow functions
Adequate bone marrow, liver, and renal functions
Adequate bone marrow, liver, and renal functions, defined as:
Adequate organ and bone marrow functions.
Patient has adequate organ and bone marrow functions:
Adequate baseline functions:
Adequate liver and renal functions
Adequate hematologic, renal, and liver functions
Adequate Hepatic functions
Adequate bone marrow, liver, and renal functions
Patients must have adequate organ functions at the time of registration:
Adequate cardiac, renal, and hepatic functions.
Adequate hematological, liver, and renal functions
Criteria 8, Adequate organ function within 4 wks prior to enrollment. This includes hematology, renal, hepatic and blood-clotting functions as defined by protocol.
Adequate organ functions (kidney, liver, cardiac, bone marrow).
Patient has adequate hematologic, hepatic, and renal functions
